Ranibizumab

In this video, Peter K. Kaiser, MD, founding director of the Digital Eye Optical Coherence Tomography Reading Center at the Cole Eye Institute, discusses navigating the treatment landscape for wet age-related macular degeneration.

BARCELONA, Spain — In this Healio Video Perspective from the Euretina congress, Timothy L. Jackson, PhD, MBChB, discusses phase 2b trial results of sozinibercept for neovascular age-related macular degeneration.

It has been nearly 3 years since the first ranibizumab biosimilar was approved for use in the U.S.

In this Healio Video Perspective from the ASRS meeting, Carl C. Awh, MD, FASRS, of Tennessee Retina discusses the phase 3 Pagoda trial investigating the port delivery system with ranibizumab for diabetic macular edema.

PARK CITY, Utah — In this Healio Video Perspective from Clinical Trials at the Summit, Arshad M. Khanani, MD, MA, FASRS, discusses efficacy and safety data for the port delivery system ahead of its reintroduction.

Genentech is set to reintroduce Susvimo for patients with wet age-related macular degeneration nearly 2 years after it voluntarily recalled the ocular implant, according to a press release.

An intravitreal injection is now the most common surgical procedure performed in the United States by an ophthalmologist.

Sandoz has completed the acquisition of Cimerli, a ranibizumab biosimilar, from Coherus BioSciences, according to a press release.

Sandoz has signed an agreement to acquire ranibizumab biosimilar Cimerli from Coherus BioSciences, according to a press release.